Public Release: 

Insilico Medicine and CBRM announce a licensing agreement on geroprotective compounds

Insilico Medicine licenses the in vitro research data from the Center for Biogerontology and Regenerative Medicine for a range of anti-aging drugs and natural products

InSilico Medicine, Inc.


IMAGE: This is the InSilico Medicine logo. view more

Credit: InSilico Medicine, Inc.

Thursday, March 17, 2016, Baltimore, MD - Insilico Medicine, Inc, and the Center for Biogerontology and Regenerative Medicine (CBRM) today entered into a licensing agreement, where Insilico obtained full rights to research results from experiments performed by and supported by the CBRM pertaining to in vitro validation of promising natural and pharmacological compounds.

In 2013 CBRM, a research organization headquartered in Moscow, Russia, sponsored a multi-center study, where multiple in silico predictions generated by scientists at Insilico Medicine were validated on in vitro on senescent cells and analyzed in multiple imaging and microarray experiments. A range of predictions with minimal or no side effects rescued the senescent phenotype and lead to transcriptomic signatures resembling "young" non-senescent cells. Insilico Medicine will receive the research results prior to publication in order to explore synergistic and cumulative effects of these compounds and perform further validation and compounding with the full rights to file for intellectual property and sub-license the findings.

"We are happy to see a list of several hundred molecules promising to extend life span could be narrowed down using computational approaches and tested in vitro. These results give us more confidence that transcriptional response- and signaling pathway activation scoring- based drug discovery strategies may help us repurpose existing safe natural products, drugs and drug combinations that may extend healthy longevity in humans or rejuvenate specific human tissues", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

The Center for Biogerontology and Regenerative Medicine is supporting multiple multi-disciplinary studies in aging and longevity, organizing industry forums and seminars for young scientists. It is dedicated to reducing Russia's dependence on natural resource-driven economy by fostering a generation of young leaders in systems biology of aging and longevity and age-related diseases. The study validating the efficacy of molecules with predicted geroprotective properties in vitro was one of the landmark research projects of CBRM.

"As a former employee of Insilico Medicine, I am happy to see that predictions we made using a novel computational approach can be validated in vitro and I hope to see this work propagate into clinical or preventative medicine practice within the coming decade. CBRM will continue performing cutting-edge experimental and clinical research to extend healthy longevity. We have one of the best teams of young scientists dedicated to preventing age-related diseases and debilitating aging-related conditions", said Andrew Garazha, president of CBRM.


About the Center for Biogerontology and Regenerative Medicine (CBRM)

The Center for Biogerontology and Regenerative Medicine was formed as a limited company in Russia to advance research in longevity research and regenerative medicine by a group of young scientists from the Pirogov Medical University, D. Rogachev Federal Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow Institute of Physics and Technology (MIPT) and Lomonosov Moscow State University specializing in bioinformatics and medicine. CBRM is affiliated with the Skolkovo Foundation and is the resident of Biopharmcluster "Northern" at the Moscow Institute of Physics and Technology (MIPT) and has close collaborations and a research agreement with the laboratory of aging and longevity.

About Insilico Medicine, Inc

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery and provides services to pharmaceutical companies. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.